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REVIEW CURRENTOPINION The different faces of the macrophage in asthmawww.co-pulmonarymedicine.ca,b, c,d,T. Anienke van der Veen , Linsey E.S. de Groot ,
and Barbro N. Melgerta,bPurpose of review
Asthma is a chronic inflammatory disease in which changes in macrophage polarization have been shown
to contribute to the pathogenesis. The present review discusses the contribution of changes in macrophage
function to asthma related to polarization changes and elaborates on possible therapeutic strategies
targeting macrophage function and polarization.
Recent findings
Macrophage function alterations were shown to contribute to asthma pathology in several ways. One is by
impaired phagocytosis and efferocytosis. Another is by changing inflammation, by altered
(anti)inflammatory cytokine production and induction of the inflammasome. Finally, macrophages can
contribute to remodeling in asthma, although little evidence is present in humans yet.
Novel therapeutic strategies targeting macrophages include dampening inflammation by changing
polarization or by inhibiting the NLRP3 inflammasome, and by targeting efferocytosis. However, many of
these studies were performed in animal models leaving their translation to the clinic for future research.
Summary
The present review emphasizes the contribution of altered macrophage function to asthma, gives insight in
possible new therapeutic strategies targeting macrophages, and indicates which knowledge gaps remain
open.
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Asthma is a heterogeneous chronic inflammatory
disease of the lungs with many phenotypes that are
all characterized by airway inflammation, reversible
airflow obstruction, airway remodeling, and bron-
chial hyperresponsiveness. The precise characteriza-
tion of these phenotypes is still evolving, but
includes divisions based on the presence of allergy,
increased numbers of eosinophils or neutrophils,
time of disease onset, response to corticosteroids,
and disease severity. In allergic asthma, allergens
can trigger bronchoconstriction and this phenotype
is associated with early-onset disease and increased
eosinophil numbers in lung. Nonallergic asthma is
associated with adult-onset disease and neutrophil
infiltration. Patients with severe asthma can have a
combination of characteristics and are usually cor-
ticosteroid resistant [1].
Although eosinophils and neutrophils are con-
sidered key determinants, the inflammatory profile
in asthma is heterogeneous with various other cells
involved. A role for macrophages in particular has
long remained understudied, although it is nowomknown that they can polarize into many different
phenotypes and that these differentially polarized
phenotypes are changed in asthma [2,3]. In the past,
a bimodal subdivision of macrophage polarizationVolume 26  Number 1  January 2020
KEY POINTS
 New treatments should focus on macrophage function
rather than identifying M1/M2 changes.
 Macrophages contribute to the pathology of asthma by
altered cellular processes such as phagocytosis,
efferocytosis, and (anti)inflammatory
cytokine production.
 Asthma is associated with defective macrophage
functions, although actual consequences may depend
on disease severity and disease phenotypes.
 Studies pinpointing the actual consequences of
macrophage (dys)function and macrophage-directed
treatment in human asthma are needed.
The different faces of the macrophage in asthma van der Veen et al.was used, dividing macrophages in M1 and M2
macrophages in a similar fashion as used for T cells
based on the expression of certain markers [4]. In
this division M1 macrophages are associated with
Th1 inflammation and considered pro-inflamma-
tory and M2 macrophages are associated with Th2
inflammation and considered pro-repair and
involved in wound healing. The bimodal subdivi-
sion has now been abandoned in favor of a model of
a spectrum of polarization changes in macrophages
that better illustrates the great variety in macro-
phage responses to stimuli [5]. A clear contribution
of changes in macrophage polarization to asthma
pathology has been shown by us and others
[2,3,6,7
&
,8,9]. Both in humans andmicewith (exper-
imental) asthma, more M1 and M2 macrophages
(old nomenclature was then used) were found in
lung tissue. However, polarization markers are
indicative of certain functions and therefore in this
review we will focus on the contribution of alter-
ations in macrophage function to asthma. In addi-
tion, we will elaborate on novel experimental
asthma therapies that target macrophage function.MACROPHAGES IN ASTHMA
Macrophages are abundantly present in lung tissue,
but their contribution to asthma pathology seems to
be through a change in function rather than num-
ber, as numbers of macrophages are unchanged in
lung tissue of patients with asthma [2,9]. Similarly,
no differences in macrophage percentages were
found in bronchoalveolar lavage fluid of asthma
and control subjects [8]. For sputum contradicting
results have been found, with more [10], less [11],
and similar [12] macrophage numbers in asthma
versus controls. These differences may be because
of asthma (pheno)type. In addition, location may1070-5287 Copyright  2019 The Author(s). Published by Wolters Kluweexplain why differences were found in sputum and
not in lung tissue. Alveolar macrophages, resident
on the alveolar epithelial surface, can be demon-
strated in sputum, but interstitial macrophages,
located within lung tissue, are not present in spu-
tum and can only be detected in tissue sections/
biopsies. Therefore, (certain types of) asthmamay be
accompanied by changes in numbers of alveolar
macrophages and not interstitial macrophages.CHANGES IN MACROPHAGE FUNCTION IN
ASTHMA
Phagocytosis
As professional phagocytes, macrophages have the
ability to recognize and eliminate pathogens and
other foreign material, thereby playing an impor-
tant role in innate immunity. In addition, several of
the markers used to denote differentially polarized
macrophages (e.g. CD64, CD163, CD206) are recep-
tors important for phagocytosis. Therefore, changes
in phagocytic behavior appear to be linked to
asthma. Several studies have reported impaired
phagocytosis of bacteria, yeasts, and particulate
matter by airway macrophages and monocyte-
derived macrophages from patients with asthma
compared to controls (reviewed by Fricker et al.
[13]). Recent findings also demonstrated less phago-
cytosis of Staphylococcus aureus by airway macro-
phages in children with neutrophil-predominant
severe asthma as compared to severe asthma with
few neutrophils [14]. Similarly, airway macrophages
from patients with noneosinophilic asthma dis-
played lower phagocytic capacity of IgG-opsonized
yeast than airway macrophages from patients with
eosinophilic asthma [15].
However, studies appear to be inconsistent
because sulfur colloid particle uptake by airway
macrophages was higher in patients with mild
asthma compared to healthy volunteers [16]. Fur-
thermore, Kulkarni et al. [17
&
] recently demon-
strated that phagocytosis of S. aureus by alveolar
macrophages from children with mild-to-moderate
asthma was similar between patients with eosino-
philic and noneosinophilic asthma and lower after
allergen avoidance for 3 weeks.
These inconsistent findings for phagocytosis are
also seen for CD163, a high-affinity scavenger recep-
tor for hemoglobin that has been investigated in the
context of asthma.More CD163þmacrophages were
found in lungs of patients with asthma with fatal
disease compared to control patients [18] and solu-
ble CD163 in sputum was also higher in asthma
compared to controls [19]. Moreover, in a mouse
model of ovalbumin-induced experimental asthma,r Health, Inc. www.co-pulmonarymedicine.com 63
Asthmaairway hyperresponsiveness and eosinophil counts
were significantly lower in CD163-deficient mice
compared to wild-type mice [18]. On the other
hand, loss of CD163 expression in house dust
mite-exposed mice was associated with enhanced
eosinophilic inflammation, possibly through higher
production of CCL24 by macrophages resulting in
more recruitment of eosinophils [20]. The same
investigators showed that CD163 can suppress
CCL24 secretion by binding of the major house dust
mite allergen, Derp1 [20].
Thus, althoughmost studies suggest that asthma
is associated with defective macrophage phagocyto-
sis, contradicting results indicate that thismaynotbe
a general phenomenon of the disease. The phago-
cytic capacity may depend on the type of material
that is being phagocytosed anddysfunctional phago-
cytosis is likelymore pronounced duringmore severe
forms of asthma, but exact mechanisms remain
poorly understood. Further characterization of
phagocytosis by macrophages and its effects on
asthma symptoms is therefore warranted.Efferocytosis
The phagocytic clearance of apoptotic cells is named
efferocytosis. In contrast to phagocytosis, this pro-
cess triggers anti-inflammatory behavior, mediated
by receptors like Mer tyrosine kinase and executed
by interleukin-10 (IL-10) production [21]. There are
fewer IL-10þ macrophages in asthma, suggesting
that efferocytosis may be impaired [2]. Indeed,
Huynh et al. [22] described lower efferocytosis of
apoptotic T cells by alveolar macrophages from
patients with severe (but not mild-to-moderate)
asthma compared to healthy volunteers. Findings
from Simpson et al. [23] also showed that efferocy-
tosis of apoptotic bronchial epithelial cells by spu-
tum macrophages was impaired in patients with
noneosinophilic asthma compared to eosinophilic
asthma, suggesting this feature may be phenotype-
specific. In contrast, recent work by Erriah et al. [24
&
]
demonstrated that efferocytosis of apoptotic gran-
ulocytes by monocyte-derived macrophages from
patients with asthma was similar compared to
healthy controls and also did not differ between
noneosinophilic and eosinophilic asthma. This
may be explained by the different origins of cells,
as in contrast to monocyte-derived macrophages,
lung macrophages are of fetal origin and more rep-
resentative of niche effects [25–27].Inflammation
Macrophages can contribute to asthmatic inflam-
mation in several ways (Fig. 1). These include altered64 www.co-pulmonarymedicine.com(anti)inflammatory cytokine/chemokine produc-
tion, induction of the inflammasome, and altered
cellular processes such as defective phagocytosis.
More M1 and M2 macrophages were found in lung
tissue of patients with asthma but whether having
M1 or M2 macrophages is related to different phe-
notypes of asthma has not been investigated yet
[2,10]. Interestingly, inhibiting either M1 or M2
polarization switched airway inflammation to more
eosinophilic or neutrophilic inflammation respec-
tively in mice [6,7
&
,28], suggesting that M1-polar-
ized macrophages lead to selective recruitment of
neutrophils whereas M2-polarized macrophages
recruit eosinophils. We are not aware of any studies
investigating which macrophage-related chemo-
kines may be responsible for this switch, but inves-
tigating this would be of major interest for
understanding the development of different
asthma phenotypes.
The changes in macrophage polarization found
in asthma and its different phenotypes are indicative
of changes in cytokine production by these cells.
Macrophages contribute to chronic airway inflam-
mation in asthma through production of proinflam-
matory cytokines such as TNFa and IL-1b. These
cytokines are implicated in many types of asthma
including neutrophilic, glucocorticoid-resistant
[29,30], and allergen-induced atopic asthma [31].
Inflammasomes are a group of multiprotein
intracellular complexes, which detect pathogenic
microorganisms and sterile stressors and activate
the production of pro-inflammatory cytokines like
IL-1b [32
&
,33]. Activation of inflammasomes inmac-
rophages starts with endogenous or microbial stim-
uli that activate nucleotide-binding oligomerization
domain-like receptors (NLRPs), of which many dif-
ferent types exist. These subsequently assemble,
bind, and activate caspase-1 and active caspase-1
proteolytically cleaves pro-IL-1b to its active inflam-
matory form [34].
These inflammasomes and their product IL-1b
are particularly interesting in the context of asthma.
The NLRP3 inflammasome for instance has been
associated with the development of asthma [33]
and single-nucleotide polymorphisms in the NLRP1
gene were shown to activate the inflammasome in
reaction to asthma-related stressors in a cohort of
Brazilian children [32
&
]. In addition, NLRPs that are
mainly expressed in macrophages and neutrophils,
are upregulated in neutrophilic asthma [32
&
,34]. In
fact, neutrophils were demonstrated to drive a proin-
flammatory phenotype in macrophages upon respi-
ratory viral infection inmice by activating theNLRP3
inflammasome in alveolar macrophages [35]. Levels
of NLRP3 have also been shown to correlate with
asthma severity and steroid resistance [30,34,36
&&
].Volume 26  Number 1  January 2020
FIGURE 1. Summary of the contribution of macrophage functions to inflammation in asthma. Macrophages can contribute to
asthma by inducing proinflammatory [29,30,31,34,57] and inhibiting anti-inflammatory cytokines [2,6,42], the inflammasome
activation [32&,33,34], changes in repair and remodeling [58–60], and defective phagocytosis and efferocytosis
[14,15,16,22,23].
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NLRP3 activation in asthma are among others apoli-
poprotein E, Charcot-Leyden crystals, and uric acid,
all well known activators of the inflammasome
[37,38]. Gordon et al. [39
&
] showed that apolipopro-
tein E secretion by human macrophages from bron-
choalveolar lavage fluid is higher after house dust
mite exposure and may therefore be responsible for
inflammasome activation. Charcot-Leyden crystals,
that form spontaneously from galectin-10 proteins
uponeosinophil lysis,were found to induce release of
IL-1b in human monocyte-derived macrophages in
an NLRP3-dependent manner and may therefore
perpetuate and exacerbate eosinophilic airway
inflammation [40
&
].Uric acid is abundantlyproduced
by human airway epithelial cells when challenged
with house dust mite [41] and can subsequently
activate the inflammasome in macrophages. Taken
together, a role for inflammasome activation inmac-
rophages in asthmatic airway inflammation is indi-
cated and may be an interesting target for therapy.1070-5287 Copyright  2019 The Author(s). Published by Wolters KluweWith respect to anti-inflammatory behavior,
fewer macrophages expressing the anti-inflamma-
tory cytokine IL-10 were found in lungs of patients
with asthma compared to controls [2]. The loss of IL-
10þ macrophages may contribute to the pathogen-
esis of asthma, as IL-10þ macrophages were shown
to prevent neutrophilic asthma inmice [42]. Indeed,
we recently showed that boosting the number of IL-
10þ macrophages, by pretreating them with PGE2
before adoptive transfer, resulted in less airway
inflammation in mice. In summary, stimulating
IL-10 production or resolving behavior is currently
unexplored avenue for novel asthma treatments [6].Tissue remodeling
Airway remodeling is an important featureof asthma,
characterized by structural airway abnormalities as a
result of collagen deposition, elastic fiber remodel-
ing, and goblet cell hyperplasia and contributing to
mucus hypersecretion and airway hyperreactivityr Health, Inc. www.co-pulmonarymedicine.com 65
Asthma[43]. Inmice,macrophageshavebeenshowntoplaya
role in repair and remodeling by detecting and elimi-
nating damaged tissue and thereby inducing repair
by regulating extracellular matrix production and by
production of growth factors, matrix metalloprotei-
nases, and their inhibitors.
However, there is little direct evidence ofmacro-
phages contributing to remodeling in patients with
asthma. Several studies, including our own, investi-
gated repair-associated macrophages (CD206þ mac-
rophages) in airwaywall biopsies or bronchoalveolar
lavage fluid of asthma patients and controls
[2,3,8,44]. We and others found that having more
CD206þ macrophages was associated with more
severe disease [2,3,44]. Although CD206þ macro-
phages are associated with remodeling, CD206
can affect collagen internalization and turnover in
vitro [45,46], we did not find correlations between
these macrophages and basement membrane thick-
ness, goblet cell numbers, or collagen deposition in
lungs of patients with asthma [2]. However, inhibi-
tion of M2 polarization in mice resulted in less
collagen deposition around airways andmore severe
airway hyperresponsiveness, indicating collagen
deposition may actually be a protective mechanism
against airway hyperresponsiveness [7
&
]. In conclu-
sion, CD206þ M2 macrophages are associated with
asthma but solid evidence of their exact role in
remodeling in humans is lacking.NEW THERAPEUTIC STRATEGIES
TARGETING MACROPHAGES IN ASTHMA
Both novel and conventional asthma treatments
affecting macrophage function have been exten-
sively summarized by Fricker et al. [13] and include
corticosteroids, macrolides, statins, phosphodiester-
ase inhibitors, leukotriene antagonists, and b-ago-
nists. Here we have focused on the most recent
findings in order to keep the reader up to date on
the latest insights. However, most of the work has
been done with in vitro or animal models, leaving
their translation to the clinic for future research.Targeting phagocytosis and efferocytosis
Phagocytosis and efferocytosis by alveolar macro-
phages is essential for lung homeostasis. Felton et al.
[47
&&
] recently showed that alveolar macrophage
efferocytosis contributed to the resolution of allergic
airway inflammation in mice, thereby making apo-
ptotic cell clearance a potential therapeutic strategy.
Since this was found to be dependent on Mer tyro-
sine kinase, augmentation of Mer activity may pro-
vide a specific mechanism to target efferocytosis.
Likewise, angiotensin-(1–7) was able to promote66 www.co-pulmonarymedicine.commacrophage efferocytosis of apoptotic cells in an
experimental mouse model of asthma [48]. This was
associated with reduced eosinophil counts, an
increase in apoptotic eosinophils, decreased nuclear
factor-kB phosphorylation, and decreased airway
remodeling and collagen deposition and therefore
resulted in resolution of inflammation and restora-
tion of homeostasis. Stimulation of efferocytosis
could also be achieved by treatment with galectin-
3 [21,24
&
]. In humans, efferocytosis by monocyte-
derived macrophages was found to be higher in
patients with asthma upon treatment of the cells
with galectin-3. Interestingly however, when strati-
fying for asthma phenotypes, this effect was only
seen in noneosinophilic asthmatics and not in
eosinophilic asthmatics. In addition, galectin-3
treatment did not result in increased efferocytosis
in healthy controls.
Similarly, inhalation of hydrogen gas improved
alveolar macrophage phagocytosis of Escherichia coli
in ovalbumin-induced asthmatic mice and allevi-
ated airway hyperresponsiveness and inflammation,
possibly because of its antioxidant effects and via
activation of nuclear factor erythroid 2-related fac-
tor two (Nrf2) [49].Modulating inflammation
Reduction of inflammation is an important goal in
the treatment of asthma. For example, corticoste-
roids have anti-inflammatory effects on macro-
phages by suppressing pro-inflammatory cytokines
like IL-1b and enhancing IL-10 production [2,13].
Recently, a few more studies have described new
therapeutic strategies to dampen inflammatory
effects of macrophages in asthma. These include
protostemonine and emodin, which were found
to attenuate dust mite-induced, ragweed-induced,
and aspergillus-induced asthmatic inflammation in
a murine model and inhibit alternatively activated
macrophage polarization [50,51]. Furthermore, the
muscarinic M3 receptor antagonist tiotropium was
shown to alleviate allergic airway inflammation
through inhibition of resistin-like molecule-a and
arginase-1 expressing (M2) macrophages in mice,
further showing the importance of M2-polarized
macrophages in asthma pathology [52]. Likewise,
treatment of RAW 264.7 macrophages with the
anti-inflammatory drug brevenal resulted in less
expression of CD86 (M1-associated) and CD206
(M2-associated), suggesting a less active state,
which resulted in less secretion of proinflammatory
cytokines [53]. Other work in lung macrophages
from mice indicated that pharmacological inhibi-
tion of sirtuin-2 not only resulted in less recruit-
ment of inflammatory cells, but also led to lessVolume 26  Number 1  January 2020
The different faces of the macrophage in asthma van der Veen et al.expressionof chitinase-likeprotein three (YM1) and
resistin-like molecule alpha, both markers associ-
ated with M2 polarization [54].
Another promising strategy for asthma treat-
ment is targeting the NLRP3 inflammasome. Inhibi-
tion of the NLRP3 inflammasome by the cytokine
release inhibitory drug CRID3 prevented airway
hyperresponsiveness and inflammation in a mouse
model of severe asthma, which was accompanied by
lower expression of IL-1b, Th2 cytokines, and che-
mokines associated with eosinophils, neutrophils,
andmacrophages [36
&&
]. Other compounds found to
inhibit NLRP3 include estrogen and some tradi-
tional herbs. Estrogen was found to suppress aller-
gen-induced airway inflammation in mice by
inhibiting NLRP3 transcription and activation [55]
and traditional herbal recipes used for asthma treat-
ment in Rwanda have recently been found to have
inhibitory effects on the interactions between
NLRP3 and caspase-1 [56].CONCLUSION
This summary of recent literature shows that the
altered function of macrophages found in asthma
may contribute to disease pathology. Current ther-
apies, primarily directed against inflammation, may
also target macrophages and modulate macrophage
function. New therapeutic strategies aiming at res-
cuing certain macrophage functions (e.g. efferocy-
tosis) indeed coincide with reduced airway
inflammation, although most of these studies still
require translation to the clinic. Future studies are
needed to pinpoint the actual consequences of mac-
rophage (dys)function and macrophage-directed
treatment in human asthma.
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